Rare Disease and Orphan Drugs Journal
All Journals
Search Log In
Home Articles Special Topics Volumes Webinars Videos
Rare Disease and Orphan Drugs Journal
Search Submit
Home Articles Special Topics Volumes Webinars Videos

REFERENCES

1. Furie RA, van Vollenhoven RF, Kalunian K, et al; LILAC Trial Investigators. Trial of anti-BDCA2 antibody Litifilimab for systemic lupus erythematosus. N Engl J Med. 2022;387:894-904.

2. Werth VP, Furie RA, Romero-Diaz J, et al; LILAC Trial Investigators. Trial of anti-BDCA2 antibody Litifilimab for cutaneous lupus erythematosus. N Engl J Med. 2022;387:321-31.

3. Furie R. Management strategies using biologics in systemic lupus erythematosus. Rare Dis Orphan Drugs J. 2025;4:22.

Submit a Manuscript
Manuscript Templates
Aims and Scope
Editorial Board
Submit a Manuscript
Manuscript Templates
Aims and Scope
Editorial Board
Rare Disease and Orphan Drugs Journal
ISSN 2771-2893 (Online)
Navigation
Follow Us
Navigation

Committee on Publication Ethics

https://members.publicationethics.org/members/rare-disease-and-orphan-drugs-journal

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/

Committee on Publication Ethics

https://members.publicationethics.org/members/rare-disease-and-orphan-drugs-journal

Portico

All published articles are preserved here permanently:

https://www.portico.org/publishers/oae/
Discover Content
Follow OAE
Twitter
Facebook
LinkedIn
YouTube
BiLiBiLi
WeChat
Rss
© 2016-2025 OAE Publishing Inc., except certain content provided by third parties